FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
The FDA has cleared Janssen Biotech's Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease worsened after platinum-based chemotherapy and immunotherapy. It's the first new approval for this patient group in a decade, backed by a 42% response rate in a 102-patient trial.
- Original source: medicalxpress.com.
- The source published it on Nov 17, 2026 at 5:19 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The U.S. Food and Drug Administration approved Janssen Biotech's Rybrevant Faspro, a combination of amivantamab and hyaluronidase-lpuj, for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed during or after platinum-based chemotherapy and immunotherapy. The clearance comes as an accelerated approval, and it marks the first drug approved for recurrent or metastatic HNSCC in patients previously treated with platinum-based chemotherapy in 10 years.
The decision rests on a trial of 102 patients with recurrent or metastatic HNSCC. Rybrevant Faspro posted an overall response rate of 42%, against 20% for currently approved therapies. Among patients who responded to the drug, 56% saw that response hold for six months or longer.
The label carries a carve-out: Rybrevant Faspro is not indicated for oropharyngeal squamous cell carcinoma linked to human papillomavirus.
Angelo De Claro, M.D., director of the FDA Oncology Center of Excellence, framed the approval as a turning point for a hard-to-treat population. In a statement, he called it a meaningful step forward for patients with HNSCC, noting that treatment options have historically been limited and outcomes remain poor.
TopicsFDA · Janssen Biotech · Rybrevant Faspro · amivantamab · Angelo De Claro · head and neck squamous cell carcinoma
Source: medicalxpress.com
Written by AI from verified reporting.
More stories
- Health & science medicalxpress.com 1 viewFDA clears Sunharbo, first factor XIa inhibitor to prevent second strokes
- Health & science france24.com 1 viewWHO warns drug resistance is outpacing the world's response
- Health & science aol.com 2 viewsFDA Approves Beren's LEMBAZ, First Drug to Improve Survival in Infantile NPC
- Health & science fiercepharma.com 1 viewGSK's Nelkarmi wins FDA nod for ALK lung cancer, capping a three-approval run

